ReviewCold Spring Harbor perspectives in biology2018
Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine.
Review in Cold Spring Harbor perspectives in biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Trial
- Advances in the Development of a Universal Influenza Vaccine.Antibodies (Basel, Switzerland) · 2026Review
- Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.Science translational medicine · 2023Article
- Differential recognition of influenza A virus H1N1 neuraminidase by DNA vaccine-induced antibodies in pigs and ferrets.Frontiers in immunology · 2023Article
- Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants.Scientific reports · 2022Article
- Next-Generation Influenza Vaccines.Cold Spring Harbor perspectives in medicine · 2021Review
- A Novel ImmunobioticsFrontiers in immunology · 2021Article
- Hide and seek: interplay between influenza viruses and B cells.International immunology · 2020Review
- Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines.JCI insight · 2019Article
- A year of terror and a century of reflection: perspectives on the great influenza pandemic of 1918-1919.BMC infectious diseases · 2019Review
- The Quest for a Truly Universal Influenza Vaccine.Frontiers in cellular and infection microbiology · 2019Review
- The post-2009 influenza pandemic era: time to revisit antibody immunodominance.The Journal of clinical investigation · 2018Article
- A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.The Journal of infectious diseases · 2018Article
- Article
- Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.Microbes and infection · 2017Article
- Quantitatively Visualizing Bipartite Datasets.Physical review. XArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Development of optimal vaccines for influenza is challenging, in part as a result of the high antigenic variability in field strains associated with genetic shift from reassortment and genetic drift from point mutations. Discovery of conserved antigenic sites on the hemagglutinin (HA) protein for neutralizing antibodies suggested the possibility that influenza vaccines could be developed that induce focused antibody responses to the conserved neutralizing determinants, especially the HA stem region. Recent studies have focused on the antigenicity and immunogenicity of such domains, using monoclonal antibodies and candidate-engineered HA stem-based vaccines. Much progress has been made, but we still do not fully understand the biology of the immune response to this unique antigenic region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.